Like you know something isn’t right with your health, but the doctor either dismissed your concerns or prescribed a ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...

Under the terms of the deal—which is expected to close ... With Vtama's success in relieving itching, Dermavant eyes FDA ...

Adbry ® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States. Adbry is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic ...

One study identified 19 patients with atopic dermatitis in a case series of 20 patients with POD (Beacham, Kurgansky, & Gould, 1990). Others found that 14% of pediatric POD cases had atopic ...

Conditions like milk rash, baby acne, cradle cap, and diaper rash can all seem alike to an untrained eye ... keep the condition under control and reduce its impact on your child’s life. The most ...

Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and ...